Fracture Monitor - Femur

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorAO Innovation Translation Center

About this trial

Thirty-seven patients diagnosed with femoral fracture to be treated with a compatible plate will be enrolled for this multicenter prospective interventional study. The Fracture Monitor T1 will be attached to the locking plate during osteosynthesis. Prior to discharge, it will be connected to an app installed either on the patients' smartphone or on the smartphone provided by the sponsor. The device will continuously collect and process data, which can automatically be downloaded via Bluetooth through the smartphone app and transferred in encrypted form to a dedicated cloud server. The smartphones will be equipped with a basic app version with rudimentary user interface that has no data visualization function. During the rehabilitation phase, data collected by the device will not be accessible to the surgeon nor the patient to ensure that no therapeutic decision will be made based on the acquired data. Every patient is treated as per standard of care.

The primary objective of the study is to collect safety information of the Fracture Monitor T1. The secondary objectives are to collect information on device performance, device handling, and usability.

All adverse events (AEs) and serious AEs (SAEs) will be recorded during the study. These will be reviewed and evaluated for their potential relationship to the device.

All patients will be followed up for 6 months after the surgery according to the local standard of care. Given that the removal of the Fracture Monitor T1 may occur beyond 6 months, a safety follow-up will take place at the time point when the Fracture Monitor T1 is removed as per the instructions for use if it has not been removed within the 6 months.

The results will be compiled into a clinical evaluation report to be submitted as part of the technical documentation for the conformity assessment procedure.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 18 years or older

Closed growth plates at time of injury

DePuy Synthes LCP® 4.5/5, Broad

DePuy Synthes LCP® 4.5/5, Broad Curved

Disqualifiers

Concomitant fractures in the contralateral leg

Electromagnetic hypersensitivity

Implanted electromagnetic bone stimulators

Pregnancy (determined by pregnancy test)

Trial design

Design model

Single group

Treatments tested in this trial

  • Fracture Monitor (implantable device class III)

    Device

    Femoral fracture fixation (bridge plating aiming at secondary bone healing) using a locking plate with an attached investigational Fracture Monitor T1.

Treatment groups

37 Participants
are divided into 1 treatment group
Group A: Fracture Monitor T1 (implantable device class III)Other 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of ADEs

To evaluate the safety, (ie the incidence of adverse device effects (ADEs), of the investigational device Fracture Monitor T1 in femoral fracture patients)

Time frame
6 months postsurgery

Secondary outcomes

1

Clinical performance: Relationship - implant load/bone healing

Relationship between relative implant load and bone healing status

Time frame
6 months
2

Clinical performance: Relationship - implant load/weight bearing

Relationship between relative implant load and prescribed weight bearing

Time frame
6 months
3

Clinical performance: Relationship - implant load/Function Index for Trauma(FIX-IT)

Relationship between relative implant load and Function Index for Trauma (FIX-IT) score FIX-IT: max 12 points - 0 worse/12 best

Time frame
6 months
4

Clinical performance: Relationship - implant load/Patient reported outcomes

Relationship between relative implant load and Patient reported outcomes: pain, EuroQol 5- dimension (EQ-5D) EQ-5D health states can be summarised using a 5-digit code or represented by a single summary number (index value) which reflects how good or bad a health state is according to the preferences of the general population of a country/region.

Time frame
6 months

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.